NVAX Stock Analysis: Buy, Sell, or Hold?
NVAX - Novavax Inc
$9.01
-0.32 (-3.45%)
▼
5d:
-3.66%
30d:
+5.23%
90d:
+10.93%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
7 traders called NVAX this week
71% bullish • 2 bearish
71% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NVAX shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: NVAX shows positive signals but monitor for confirmation. Market pricing in 0% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $9.01, which is considered fair relative to its 30-day fair value range of $8.81 to $9.56. From a valuation perspective, the stock is trading at a discount (Forward PE: -36.7) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $8.53, while resistance sits at $10.12. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.11 (+51.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NVAX is in a uptrend. Immediate support is located at $8.53, while resistance sits at $10.12. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.11 (+51.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.81 -
$9.56
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 51.3% below Wall St target ($14.11)
Trading Range Analysis
30-Day Trading Range
$8.81 -
$9.56
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.53
Resistance Level
$10.12
Current Trend
Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-36.66
Wall Street Target
$14.11
(+51.3%)
Revenue Growth (YoY)
-79.1%
Earnings Growth (YoY)
-38.1%
Profit Margin
-14.7%
PE vs Historical
-36.7 vs 35.1
CHEAP
Share & Embed Analysis
Last updated: July 13, 2026 12:43 PM ET
Data refreshes hourly during market hours. Next update: 1:43 PM
Data refreshes hourly during market hours. Next update: 1:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 64 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 53 HOLD |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
